Obulwadde bwa Catastrophic Antiphospholipid Syndrome (CAPS / Asherson’s Syndrome): Omuyaga gw’okusannyalala kw’emisuwa emitonotono egy’ebitundu bingi mu wiiki emu n’obujjanjabi obw’emirundi esatu n’obulwadde bwa Plasmapheresis¶

Obulwadde bwa katyabaga obulwaza obulwadde bwa Antiphospholipid Syndrome (CAPS, era erinnya lye emanyiddwa nga Asherson's Syndrome oluvannyuma lwa Dr. Ronald Asherson, eyasooka okukinnyonnyola mu 1992) ye nkyukakyuka esinga okubeera ey’amaanyi, etta obulamu bwa Antiphospholipid Syndrome (APS), okukuba ekitono okusinga 1 percent wa abalwadde ba APS (with nearly 50 percent of cases occurring as the very first clinical presentation in a patient who never knew they had APS). So nga APS eya classic etera okuleeta okuzimba emisuwa oba emisuwa eminene (such as a single deep vein thrombosis, pulmonary embolism, or stroke) oba okufiirwa olubuto oluddirira, CAPS ye "thrombotic storm" etulika, egaziyizibwa ebijjuliza (Thrombotic Microangiopathy [TMA] + obulwadde bw’okuddamu okuzimba mu nkola [SIRS]) ekiziba omulundi gumu obusimu obutonotono obw’ensengekera z’ebitundu ensengekera z’ebitundu ssatu oba okusingawo mu nnaku ezitakka wansi wa 7, okusinga ensigo (73%: puleesa embi, proteinuria, n'okulemererwa kw'ekibumba okw'amaanyi), amawuggwe (60%: ARDS, okuzimba amawuggwe, n’okuvaamu omusaayi mu nnyindo okusaasaana), obwongo (56%: okusannyalala, okukonziba, okuzimba emisuwa gy’obwongo, n’obulwadde bw’obwongo), omutima (50%: okuzimba emisuwa gy’omutima n’ebimera bya vvaalu ya Libman-Sacks), olususu (47%: livedo racemosa, obulumi digital ischemia, n'okufa kw'olususu), ne endwadde z'ekibumba (bilateral adrenal hemorrhage/infarction causing refractory hypotensive shock). Kubanga CAPS evugirwa enkola ya "Two-Hit", nga eno antibodies eza high-titer antiphospholipid ezaaliwo edda (Lupus Anticoagulant [LA], . Anti-Cardiolipin [aCL] IgG/IgM, era Anti-Beta-2-Glycoprotein-I [aB2GPI] IgG/IgM) zikoleezebwa ekiziyiza eky'amaanyi ekya "Second Hit" (bacterial or viral infection in 49%, surgical procedures or trauma in 17%, abrupt withdrawal or subtherapeutic INR of Warfarin, malignancy, pregnancy/puerperium, or oral contraceptive estrogen), okulwawo obujjanjabi kitwala ** .80 to 90 percent omuwendo gw'abafa**, so nga okutandika amangu ICU CAPS "Triple Therapy" kusala ku kufa mu bitundu bibiri. Singa omulwadde alina Lupus amanyiddwa (SLE), Antiphospholipid Syndrome, oba thrombocytopenia etategeerekeka efuna obubonero obw’amangu obw’ebitundu ebingi (shortness of breath, confusion, chest or flank pain, mottled purple skin, or dark/absent urine), kuba essimu y’omu kitundu kyo ennamba z’amangu amangu ago. Era weetegereze ebiragiro byaffe ebikolagana nabyo ku obuzibu bw’ekibumba n’empiso ey’amangu ey’obulwadde bwa Addison, . okukonziba kw’obulwadde bwa eclampsia, obulwadde bwa HELLP syndrome, n’obulwadde bw’okuzaala nga tebannaba kuzaala, era sepsis ne septic shock.

Ekitongole kyo eky'amangu eky'amangu ne ICU ekikulu kwe okutongoza "CAPS Triple Therapy" mu bujjuvu empiric omulundi gumu ku kuteebereza okusooka ennyo okw'obujjanjabi okw'okuzimba emisuwa emitonotono egy'ebitundu bingi (WITHOUT waiting days for confirmatory antiphospholipid antibody titers or tissue biopsy): (1) Enzijanjaba ey’okuyisibwa mu misuwa Heparin etali ya bitundutundu (UFH) ( ) .not only to halt fibrin clot propagation, but because heparin directly inhibits complement activation [C3/C5 convertase]), (2) Eddagala eriweweeza ku bulwadde bwa Corticosteroids eriweebwa mu misuwa erya dose ennene (Methylprednisolone 500 to 1,000 mg/day IV for 3 days, followed by 1 to 2 mg/kg/day) ( ) .to extinguish the NF-kappa-B endothelial cytokine storm), ne (3) Okuwanyisiganya Plasma okw’obujjanjabi okw’amangu buli lunaku (Plasmapheresis / TPE okuwanyisiganya obuzito bwa pulasima 1.0 ku 1.5 ku Fresh Frozen Plasma/Albumin) NE/OBA Immunoglobulin ey’omu misuwa ey’amaanyi (IVIG, . 0.4 g/kg/day IV for 5 days), nga bwe bajjanjaba ekizibu ekisiiga obulwadde obusirikitu n’eddagala eritta obuwuka erya broad-spectrum era nga bateeka mu nkola anti-C5 terminal complement inhibitor Eculizumab (Soliris) oba okulwanyisa CD20 Rituximab ku misango egitaziyiza.

Kino kikole kati¶

1. Kuba ennamba yo ey’amangu mu kitundu kyo oba trigger ICU / Hematology / Rheumatology Rapid Response ey’amangu singa omulwadde afuna thrombosis oba acute organ dysfunction mu kiseera kye kimu mu >= 2 to 3 ebitundu by’omubiri mu wiiki emu. Dial 911 mu Amerika ne Canada, . 999 mu Bungereza, 112 okwetoloola omukago gwa Bulaaya, . 000 mu Australia, oba weebuuze ku dayirekita yaffe eya ennamba z’amangu. Jjukira nti 46 to 50 percent ku balwadde ba CAPS tebalina kuzuulibwa nga tebannaba kuzuula APS oba Lupus (SLE) nga tonnatambula mu kisenge ky’abalwadde ab’amangu.
2. Tandika Empagi 1 ey’Obujjanjabi bwa CAPS Triple Therapy Amangu: Obujjanjabi Heparin Obutagabanyiziddwa mu Misuwa (UFH) ( ) ( ) .Even in the Presence of Moderate Thrombocytopenia or Diffuse Alveolar Hemorrhage).
3. Heparin etali ya bitundutundu lye jjinja ery’oku nsonda ery’ekiragiro eri okuwangaala kwa CAPS (reducing mortality from > 75% to about 30% mu International CAPS Registry) byombi nga biyita mu antithrombin-mediated anticoagulation n’okuziyiza obutereevu okuziyiza amakubo ga classic ne alternative complement.
4. Lulu y'okulondoola mu laboratory enkulu (The Lupus Anticoagulant aPTT Trap): Kubanga omulwadde atambula omusaayi Lupus Anticoagulant (LA) obutafaali obuziyiza endwadde buwanvuya mu ngeri ey’ekikugu omusingi ogwesigamye ku phospholipid ** .aPTT** (often to 60 to 100+ seconds nga heparin tennatandika wadde), okulondoola IV unfractionated heparin n’omutindo aPTT ajja kukulimba n'ofuna okunywa ennyo heparin. Bulijjo londoola IV Unfractionated Heparin mu CAPS ng’okozesa chromogenic Anti-Factor Xa (Anti-Xa) okukebera (target 0.3 to 0.7 IU/mL), NEVER omutindo aPTT.
5. Tandika Empagi 2 eya CAPS Triple Therapy Amangu: Pulse Intravenous Methylprednisolone (500 to 1,000 mg IV Once Daily for 3 Consecutive Days, Okugobererwa... 1 to 2 mg/kg/day IV). Towa ddagala lya corticosteroids zokka nga tolina anticoagulation mu CAPS, naye ku mabbali ga IV Heparin ne Plasmapheresis, dose ennene IV Methylprednisolone eggalawo Anti-Beta-2-Glycoprotein-I (aB2GPI) okukola kw’endothelial NF-kappa-B era Tissue Factor okwolesebwa era mu kiseera kye kimu kubikka acute bilateral adrenal hemorrhage/infarction (which complicates 13% to 26% of CAPS cases).
6. Tandika Empagi 3 eya CAPS Triple Therapy Mu Ssaawa Ntono: Okuwanyisiganya Plasma mu Bujjanjabi Buli Lunaku (Plasmapheresis / TPE) NE/OBA Immunoglobulin Ya Dozi Ennene Eyingizibwa mu Misuwa (IVIG).
7. Okuwanyisiganya Plasma mu ngeri ey'obujjanjabi (TPE, Layini esooka naddala nga Schistocytes / Microangiopathic Hemolytic Anemia [MAHA] oba Okulemererwa kw'ekibumba biriwo): Okuwanyisiganya ** .1.0 to 1.5 plasma volumes buli lunaku okumala waakiri ennaku 3 ku 5** ng’okozesa Fresh Frozen Plasma (FFP) (or 50:50 FFP + 5% Albumin) okuggyamu ebyuma mu ngeri ey’ebyuma aB2GPI era aCL obuziyiza obuziyiza endwadde, cytokines ( .IL-1, IL-6, TNF-alpha), era nga zijjuliza ebitundutundu ate nga zijjuza eddagala ery’obutonde eriziyiza okuzimba omusaayi (Antithrombin, Protein C, Protein S, and ADAMTS13).
8. Dozi ya waggulu IVIG (0.4 g/kg/day IV for 5 days oba 1.0 g/kg/day for 2 days): Muwe oba wekka (ssinga okuteekebwa kwa apheresis catheter oba TPE kulwawo) oba amangu ddala nga buli lunaku lwa Plasma Exchange session (never infuse IVIG right *before* a TPE session, or the apheresis machine will wash your expensive IVIG straight into the waste bag).
9. Muyigga era ojjanjabe n'obusungu "Second-Hit" Precipitating Trigger (Infection in 49% of Cases). Kuba ekifaananyi kya STAT eky’omusaayi ogw’okumpi ne layini, obuwangwa bw’omusulo, n’ebipande by’akawuka, era otandike empiric broad-spectrum intravenous antibiotics amangu ddala singa wabaawo omusujja oba ensibuko y’obulwadde yonna eteeberezebwa. Toyimiriza mu ngeri ya kimpowooze anticoagulation nga tonnalongoosebwa mu mulwadde amanyiddwa a Triple-Positive APS (always bridge closely with IV UFH or therapeutic LMWH).
10. Muteeka mu nkola Terminal Complement Okuziyiza (IV Eculizumab 900 mg Buli wiiki) oba Rituximab Nga bukyali mu Refractory CAPS oba Prominent TMA (Schistocytes + Severe Thrombocytopenia + Renal Failure). Obujulizi obw’okugezesa n’obw’obujjanjabi bukakasa nti CAPS ey’amaanyi evugirwa **Terminal Complement Complex (Terminal Complement Complex) edduse (runway Terminal Complement Complex)C5b-9 membrane attack complex) okuteekebwa ku butoffaali bw’omubiri (often with underlying complement regulatory gene mutations). Okuwa IV Eculizumab ( .Soliris) eyimiriza okuzimba omusaayi mu misuwa, okukendeeza omusaayi mu misuwa, n’okuzimba emisuwa emitonotono mu kibumba mu ssaawa 48 okutuuka ku 72 nga enkola ya Triple Therapy eya bulijjo temala.

Omuti gw’okusalawo: ateeberezebwa okuba n’obulwadde bwa Catastrophic Antiphospholipid Syndrome (CAPS / Asherson’s Syndrome) n’obujjanjabi bwa ICU Triple Therapy¶

flowchart TD
    Patient["Omulwadde Yeyanjula N’obuzibu bw’ebitundu ebingi obugenda mu maaso amangu (>= ebitundu 3 mu nnaku < 7):<br/>- Ekibumba: Obuvune obw’amaanyi mu kibumba, HTN embi, Proteinuria<br/>- Amawuggwe: ARDS / Diffuse Alveolar Hemorrhage / PE<br/>- CNS: Encephalopathy, Stroke, Okukonziba, CVST<br/>- Omutima: Troponin erinnye, Myocardial Microthrombi<br/>- Olususu: Livedo Racemosa, Digital Gangrene, Olususu Necrosis<br/>- Ekibumba: Obulumi mu mabbali/olubuto + Puleesa etali ya maanyi"] --> StatWorkup["STAT Bedside & Lab Triage (TOlwawo kujjanjaba ku biva mu antibody):<br/>1. Okusiiga ebitundu by’omubiri (Schistocytes), LDH, Haptoglobin, Ebiwuka ebiyitibwa Platelets, Coags, Fibrinogen<br/>2. Kuba ekifaananyi ky’eddagala eriziyiza okuzimba omusaayi mu lupus (dRVVT/aPTT), Anti-Cardiolipin IgG/IgM, & Anti-Beta-2-Glycoprotein-I IgG/IgM (NGA TEBONA kuwanyisiganya Plasma)<br/>3. Draw Random Cortisol & ACTH (Kebera oba omusaayi guvaamu omusaayi mu nnyindo bbiri) + ADAMTS13 Activity (Rule Out TTP)"]

    StatWorkup --> TripleTherapy["TONGOZA EMPIRIC 'CAPS TRIPLE THERAPY' MAGANDA MU ICU"]

    TripleTherapy --> Pillar1["PILLAR 1: Therapeutic IV Unfractionated Heparin (UFH)<br/>- Londoola nnyo n’omutindo gwa Chromogenic ANTI-FACTOR Xa (Ekigendererwa 0.3 okutuuka ku 0.7 IU/mL)<br/>- TOLONDAKO na Standard aPTT (Ekiwanvuwa mu bukyamu nga Lupus Anticoagulant)"]

    TripleTherapy --> Pillar2["EMPIMBI 2: Eddagala lya dose ennene IV Corticosteroids<br/>- IV Methylprednisolone 500 ku 1,000 mg Buli lunaku okumala Ennaku 3, Olwo 1 ku 2 mg/kg/olunaku<br/>- Eziyiza NF-kappa-B Endothelial Storm & Ejjanjaba Adrenal Crisis"]

    TripleTherapy --> Pillar3["EMPIMBI 3: Okuwanyisiganya Plasma mu Bujjanjabi (TPE) buli lunaku +/- IVIG ya dose ennene<br/>- Okuwanyisiganya obuzito bwa Plasma 1.0 ku 1.5 Buli lunaku x Ennaku 5+ nga okozesa Fresh Frozen Plasma (FFP)<br/>- Fuuwa IVIG (0.4 g/kg/olunaku x Ennaku 5) OLUVANNYUMA lwa Buli TPE Session (Never Right Before TPE)"]

    Pillar1 --> TriggerAndRefractory{"Jjanjaba 'Second-Hit' Trigger (Empiric Broad-Spectrum Antibiotics singa wabaawo Infection) & Kebera Okuddamu okuva ku ssaawa 24 okutuuka ku 48"}
    Pillar2 --> TriggerAndRefractory
    Pillar3 --> TriggerAndRefractory

    TriggerAndRefractory -->|"Refractory Thrombocytopenia, Ongoing MAHA Schistocytes, oba Okulemererwa kw’ebitundu by’omubiri okweyongera"| AddEculizumab["ESCALATE IMMEDIATELY:<br/>1. IV Eculizumab (Anti-C5 Complement Inhibitor: 900 mg IV Weekly x 4, Then 1,200 mg) [Give Meningococcal Vaccine + Ciprofloxacin/Penicillin Prophylaxis]<br/>2. IV Rituximab (375 mg/m2 Weekly x 4) to Deplete B-Cell Autoantibody Production"]

Ekitundu 1: Enkola ya "Two-Hit" Pathophysiology of Asherson's Syndrome n'emisingi gy'ensi yonna egy'okuzuula¶

1. Lwaki Antiphospholipid Antibodies ezisirise zitulika mu bwangu ne zifuuka omuyaga ogw’ebitundu ebingi ogw’ennaku 7¶

Abantu bangi ssekinnoomu batambula okumala emyaka nga balina obutoffaali obuziyiza phospholipid obutambula "Triple-Positive" (Lupus Anticoagulant + Anti-Cardiolipin + Anti-Beta-2-Glycoprotein-I) nga tofunye kuzimba musaayi ("The First Hit"). Lwaaki? Kubanga mu mbeera eya bulijjo ey’okuwummula, obutoffaali bw’emisuwa obuyitibwa endothelial cells bukweka phospholipids z’olususu ezirina omusannyalazo omubi ku lupapula lwazo olw’omunda, era ezitambula Beta-2-Glycoprotein-I (B2GPI) etengejja mu nsengekera ey’enkulungo enzigale ekweka ekitundu kyayo eky’okusiba antigenic (Domain I).

• Ekiziyiza "Okukuba Ow'okubiri" (Infection, Surgery, Trauma, Pregnancy, or Warfarin Withdrawal):
• Bwe wabaawo yinfekisoni (Gram-negative sepsis, respiratory virus, urinary tract infection).
• Okutambula ** .B2GPI** esiba ku endothelium eyonoonese n'esumulula mu nsengekera ya "J-shaped fishhook" eggule, n'ebikkula Domain I.
• Obulwadde obuleeta endwadde Anti-Beta-2-Glycoprotein-I (aB2GPI) IgG dimers zisalasala ebiggule B2GPI molekyu ku butoffaali bw’omubiri, platelets, ne monocytes nga ziyita mu Toll-Like Receptor 4 (TLR4) and Annexin A2, activating NF-kappa-B ne ** .p38 MAPK**.
• The Complement Amplification Loop (C3a / C5a / C5b-9): The bound aB2GPI immune complexes trigger massive activation of the Classical and Alternative Complement Pathways, generating anaphylatoxins C3a era C5a (which recruit neutrophils to extrude prothrombotic NETs) and punching C5b-9 Membrane Attack Complex pores into microvascular endothelial cells throughout the kidneys, lungs, brain, heart, and adrenal glands.

2. Official Preliminary Classification Criteria for Catastrophic APS (Asherson et al. International Consensus) .¶

Clinicians classify a patient as having Definite CAPS (all 4 criteria) or Probable CAPS (3 of 4 criteria) based on: 1. Criterion 1 (>= 3 Organs, Systems, or Tissues): Clinical evidence of involvement of three or more organs, systems, and/or tissues (renal, pulmonary, cerebral, cardiac, cutaneous, hepatic, gastrointestinal/mesenteric, splenic, or adrenal). 2. Criterion 2 (<= 7 Days): Development of clinical manifestations simultaneously or in less than one week. 3. Criterion 3 (Histopathologic Microthrombosis): Confirmation by histopathology of small-vessel occlusion (thrombotic microangiopathy) in at least one organ or tissue (typically via skin punch biopsy of livedo/necrotic lesions or renal biopsy once stabilized). 4. Criterion 4 (Laboratory Antiphospholipid Antibodies): Presence of Lupus Anticoagulant (LA), Anti-Cardiolipin (aCL IgG/IgM at medium-to-high titer > 40 GPL/MPL oba > 99th percentile), and/or Anti-Beta-2-Glycoprotein-I (aB2GPI IgG/IgM).

• When to Diagnose "Probable CAPS" and Treat Immediately at the Bedside: Because performing a kidney biopsy in a critically ill, anticoagulated, thrombocytopenic ICU patient is dangerous and waiting 12 weeks for repeat antibody confirmation is impossible during an acute crisis, the International Consensus defines Probable CAPS whenever:
• Only 2 organs are involved (with Criteria 2, 3, and 4 met), OR
• All 4 criteria are met except histopathologic biopsy confirmation is missing (because the patient is too unstable/anticoagulated to biopsy), OR
• 3 organs develop thrombosis over 1 to 4 weeks despite anticoagulation.
• Clinical Rule: Treat Probable CAPS identically to Definite CAPS with immediate full Triple Therapy.

Part 2: Side-by-Side Differential Diagnosis of ICU Thrombotic Microangiopathies (CAPS vs. TTP vs. HUS/aHUS vs. HIT vs. Sepsis DIC) .¶

When an ICU patient develops rapidly falling platelets, rising creatinine, neurological confusion, and hemolytic anemia with schistocytes (helmet cells) on the blood smear, distinguishing CAPS from Thrombotic Thrombocytopenic Purpura (TTP), Complement-Mediated Hemolytic Uremic Syndrome (aHUS), HIT, and Septic DIC is critical:

Part 3: Deep-Dive Into the 6 Organ Emergencies of CAPS (Including Bilateral Adrenal Hemorrhage & Diffuse Alveolar Hemorrhage)¶

When managing a CAPS patient in the ICU, clinicians must actively screen for and manage six signature organ crises that determine survival:

========================================================================
   THE 6 SIGNATURE MULTI-ORGAN THROMBOTIC CRISES OF CAPS (ASHERSON'S)
========================================================================

  1. RENAL TMA (73%):               2. PULMONARY CRISIS (60%):
     Renal interlobular/glomerular     ARDS, Pulmonary Embolism, AND
     capillary microthrombi ->         Capillaritis DIFFUSE ALVEOLAR
     Malignant HTN + Oliguric AKI.     HEMORRHAGE (DAH: Hemoptysis +
                                       Falling Hb + Ground-Glass CT).
  3. CEREBRAL / CNS (56%):             * CRITICAL PEARL: Even with DAH,
     Microvascular Encephalopathy,       continue carefully titrated IV
     Seizures, Ischemic Stroke, &        Heparin + Pulse Steroids + TPE.
     Cerebral Venous Sinus Clots.
                                    4. CARDIAC MICRO-INFARCTION (50%):
  5. CUTANEOUS ISCHEMIA (47%):         Intramyocardial microthrombi
     Branching Livedo Racemosa,        (cardiogenic shock with clean
     Splinter Hemorrhages, Digital     epicardial coronaries) + Sterile
     Cyanosis/Gangrene, Skin Ulcers.   Libman-Sacks Mitral/Aortic Valves.

  6. BILATERAL ADRENAL HEMORRHAGE / INFARCTION (13% to 26% - OFTEN MISSED.):
     * Why the Adrenal Glands? Each adrenal gland is fed by 3 arteries
       (50-60 arterioles) but drained by ONLY A SINGLE CENTRAL ADRENAL VEIN.
     * Thrombosis of that single central adrenal vein causes hemorrhagic
       venous infarction of both adrenal cortices -> Sudden Flank/Abdominal
       Pain, Hyponatremia, Hyperkalemia, & Catecholamine-Resistant Shock.
     * Lifesaving Fix: Immediate Stress-Dose IV Hydrocortisone (100 mg IV
       bolus, then 50 mg IV q6h) or Pulse IV Methylprednisolone.
========================================================================

1. The Adrenal Vein Anatomical Bottleneck (Why CAPS Causes Acute Addisonian Adrenal Crisis) .¶

Why is bilateral adrenal hemorrhage/infarction a classic complication of both CAPS and HIT? - Every human adrenal gland has a rich arterial supply (superior, middle, and inferior suprarenal arteries branching into 50+ capillary plexus vessels), but all venous blood must exit through a single, solitary Central Adrenal Vein (creating a vascular "water-hammer" bottleneck rich in platelet-activating catecholamines). - When CAPS microthrombi occlude that single central adrenal vein bilaterally, venous pressure inside the adrenal cortex skyrockets until the glands rupture and hemorrhage internally (Waterhouse-Friderichsen-like hemorrhagic infarction). - Clinical Red Flags: If a patient with APS/CAPS develops new bilateral flank, back, or epigastric pain, unexplained fever, falling serum sodium (hyponatremia), rising potassium (hyperkalemia), and hypotension refractory to norepinephrine, order an immediate Abdominal CT (which shows enlarged, hyperdense edematous adrenal glands), draw a STAT random serum Cortisol and ACTH, and immediately administer 100 mg IV Hydrocortisone bolus followed by 50 mg IV buli ssaawa 6 (or make sure the patient is already receiving Pulse IV Methylprednisolone).

2. The Pulmonary Paradox: Managing Diffuse Alveolar Hemorrhage (DAH) Inside a Prothrombotic Storm¶

Up to 60 percent of CAPS patients develop acute respiratory failure from ARDS, pulmonary thromboembolism, or non-thrombotic pulmonary capillaritis causing Diffuse Alveolar Hemorrhage (DAH: hemoptysis, diffuse bilateral alveolar infiltrates on chest CT, and a 1.5 to 3.0 g/dL overnight drop in hemoglobin). - How Can a Clotting Disease Cause Lung Bleeding? In CAPS, aB2GPI antibodies and C5a trigger immune-complex pulmonary capillaritis (neutrophilic inflammation that necroses the alveolar capillary wall) combined with pulmonary venular microthrombosis that raises hydrostatic capillary back-pressure until red blood cells pour into the air sacs. - How to Manage DAH in CAPS: 1. Immediately escalate immunosuppression with Pulse IV Methylprednisolone (1,000 mg/day IV x 3 days) + Daily Therapeutic Plasma Exchange (TPE) + IV Cyclophosphamide or Rituximab. 2. Carefully Balance Anticoagulation: If alveolar bleeding is life-threatening and platelets/fibrinogen are critically low, hold IV unfractionated heparin briefly for a few hours while administering Pulse Steroids and Plasma Exchange, but resume low-dose/titrated IV Unfractionated Heparin as soon as active hemoptysis stabilizes, because withholding heparin for days in CAPS allows microvascular thrombosis to destroy the brain, heart, and kidneys.

Part 4: Step-by-Step ICU Triple Therapy Execution & Refractory Rescue (Eculizumab & Rituximab) .¶

1. The Exact CAPS Triple Therapy Checklist (McMaster / EULAR / International CAPS Registry Guidelines) .¶

2. Second-Line Biologic Rescue for Refractory CAPS (Eculizumab era Rituximab) .¶

Singa omulwadde wa CAPS agenda mu maaso n’okufuna platelets ezigwa, creatinine okulinnya, obuzibu obupya mu busimu, oba refractory microangiopathic hemolysis oluvannyuma lw’essaawa essaawa 24 ku 48 ez’obujjanjabi bwa Triple Therapy: 1. Terminal Complement Blockade (IV Eculizumab [Soliris] oba Ravulizumab [Ultomiris]): - Why It Works: Over 60 percent of patients with refractory CAPS harbor severe complement activation (and many carry heterozygous mutations in complement regulatory genes like CFH, CFI, or CD46 identical to atypical HUS). Eculizumab (a humanized monoclonal antibody against complement protein C5) blocks cleavage of C5 into C5a era C5b-9, arresting endothelial TMA destruction within 24 to 72 hours. - Dosing: 900 mg IV once weekly for 4 weeks, followed by 1,200 mg IV on Week 5 and every 2 weeks thereafter. - Mandatory Meningococcal Prophylaxis: Because blocking C5b-9 creates susceptibility to encapsulated Neisseria meningitidis, administer quadrivalent (MenACWY) and Serogroup B (MenB) meningococcal vaccines immediately AND start daily oral antibiotic prophylaxis (Ciprofloxacin 500 mg daily oba Penicillin V 500 mg twice daily) from Day 1 of Eculizumab (do not delay Eculizumab for 2 weeks waiting for vaccine immunity). 2. B-Cell Depletion (IV Rituximab): - Administer Rituximab (375 mg/m2 IV omulundi gumu buli wiiki okumala wiiki 4, oba 1,000 mg IV on Days 1 and 15) (infused after daily TPE) to eliminate CD20+ B-lymphocytes producing pathogenic antiphospholipid autoantibodies, particularly in CAPS patients with severe thrombocytopenia, diffuse alveolar hemorrhage, or cardiac/CNS involvement.

Regional emergency numbers and international CAPS registries¶

• United States and Canada: Dial 911 for any suspected multi-organ thrombosis or stroke/PE emergency. Follow the McMaster University Clinical Practice Guideline for the Diagnosis and Management of Catastrophic Antiphospholipid Syndrome (Blood Advances) and American College of Rheumatology (ACR) / ASH guidance.
• European Union and United Kingdom: Dial 112 across the EU or 999 in the UK. Follow the European Alliance of Associations for Rheumatology (EULAR) Recommendations for the Management of Antiphospholipid Syndrome in Adults (Tektonidou et al., Annals of the Rheumatic Diseases) and the British Society for Haematology (BSH) Guidelines. Clinicians worldwide can consult and log cases with the International CAPS Registry (ontocrf.costaisa.com/en/web/caps, hosted by the European Forum on Antiphospholipid Antibodies at Hospital Clínic in Barcelona, Spain, directed by Dr. Ricard Cervera).
• Australia and New Zealand: Dial 000 in Australia or 111 in New Zealand. Follow THANZ and Australian Rheumatology Association (ARA) ICU protocols for Triple Therapy and emergency Eculizumab access.

Ebibuuzo ebitera okubuuzibwa¶

How is Catastrophic Antiphospholipid Syndrome (CAPS) different from regular Antiphospholipid Syndrome (APS)?¶

In classic Antiphospholipid Syndrome (APS), patients typically experience a single isolated blood clot in a large vein or artery (such as a deep vein thrombosis in one leg, a pulmonary embolism, or a stroke) or recurrent pregnancy complications, with normal function in the rest of their organs. Catastrophic Antiphospholipid Syndrome (CAPS, or Asherson's Syndrome) affects less than 1 percent of APS patients and acts like a sudden, body-wide microvascular "thrombotic storm": instead of one large clot, tiny blood clots simultaneously plug the microscopic capillaries of three or more critical organs (usually the kidneys, lungs, brain, heart, skin, and adrenal glands) within less than 7 days, accompanied by severe systemic inflammation and a falling platelet count.

Lwaki abasawo balina okuwa obujjanjabi busatu mu kiseera kye kimu ddala ("Triple Therapy") okutaasa omulwadde alina CAPS?¶

Ebiwandiiko by’ebyafaayo okuva mu International CAPS Registry (ebikwata ku balwadde abasukka mu 500 mu nsi yonna) byakakasa nti okujjanjaba CAPS n’eddagala erikendeeza omusaayi lyokka oba steroids zokka kyalemererwa mu mbeera ezisinga obungi, kubanga CAPS erina yingini ssatu ezeenyweza: (1) Runaway fibrin and complement clotting in small vessels, (2) A fierce inflammatory cytokine storm on the blood vessel ebisenge, ne (3) Ebirungo ebingi eby’obutoffaali obuziyiza phospholipid autoantibodies obutambula. "Triple Therapy" elumba yingini zonsatule omulundi gumu: Intravenous Unfractionated Heparin eyimiriza okusaasaana kw'okuzimba n'okuziyiza complement, High-Dose IV Methylprednisolone eggalawo omuyaga gwa endothelial cytokine, ne Daily Therapeutic Plasma Exchange (Plasmapheresis) ne/oba IVIG eggyawo mu mubiri n'ezifuula autoantibodies, okusala okufa okuva ku bitundu ebisukka mu 75 ku buli 100 okukka okutuuka ku bitundu nga 30 ku buli 100.

Lwaki ba nurse n’abasawo tebasobola kukozesa standard aPTT blood test okulondoola Heparin eyingizibwa mu misuwa mu mulwadde alina CAPS?¶

Abalwadde abalina CAPS kumpi bulijjo baba n'ekirungo ekiziyiza phospholipid ekitambula ekiyitibwa "Lupus Anticoagulant" (LA). Ekyewuunyisa, wadde nga Lupus Anticoagulant ereeta omusaayi okuzimba ennyo munda mu mubiri gw’omuntu, munda mu ttanka y’okukebera mu laboratory ey’endabirwamu yeesiba ku bikozesebwa mu kukola phospholipid reagents ebikozesebwa okuddukanya okukebera kwa standard activated Partial Thromboplastin Time (aPTT), mu ngeri ey’ekikugu ne kifuula aPTT y’omulwadde eya baseline okulabika ng’ewanvuye (okugeza, sekondi 85) nga n’ettondo limu erya heparin terinnaweebwa. Singa omusawo akozesa aPTT okulongoosa amatondo g'ekibumba, mu bukyamu ajja kulowooza nti omusaayi gw'omulwadde "gugonvu nnyo" era ne gukendeeza ku matondo g'ekibumba okutuuka ku mutindo ogutali gwa bujjanjabi ate omulwadde n'azimba n'afa. Wabula, IV Heparin mu CAPS bulijjo erina okulondoolebwa n’omutindo gw’omusaayi oguyitibwa chromogenic Anti-Factor Xa (Anti-Xa) (nga gugenderera 0.3 ku 0.7 IU/mL), ogutakosebwa Lupus Anticoagulant.

Lwaki CAPS etera okuleeta obulwadde bwa Adrenal Crisis (Addisonian shock) obw’amangu, obutta obulamu?¶

Buli emu ku nseke zo ebbiri ez’ekibumba (ezituula waggulu ku kibumba ne zikola cortisol ne aldosterone eziyimirizaawo obulamu) efuna omusaayi okuyita mu misuwa emitonotono amakumi, naye n’efulumya omusaayi gwayo gwonna okuyita mu Central Adrenal Vein emu emu. Mu kiseera ky’omuyaga gwa CAPS thrombotic storm, micro-clots mangu okuziba omusuwa ogwo ogumu ogufulumya amazzi ku njuyi zombi. Nga omusuwa ogufuluma guzibiddwa, omusaayi gw’emisuwa gudda emabega munda mu nnywanto zombi ez’ekibumba okutuusa lwe zizimba ne zikutuka munda (okuvaamu omusaayi mu nnyindo ku njuyi zombi n’okuzimba). Kino kisangula omubiri okukola cortisol ekiro kimu, ekivaako obulumi obw’amaanyi mu ludda oba mu lubuto, sodium omutono, potassium omungi, ne puleesa entono etta okuggyako ng’ojjanjabiddwa mangu n’eddagala eriweebwa mu misuwa erya dose ennene (Methylprednisolone oba Hydrocortisone).

Why should patients with Triple-Positive APS or prior CAPS never be switched from Warfarin to a modern Direct Oral Anticoagulant (DOAC) pill like Rivaroxaban or Apixaban?¶

Okugezesebwa okw'obujjanjabi okungi okwa randomized (nga mw'otwalidde n'okugezesebwa kwa TRAPS ne ASTRO-APS) kwayimirizibwa nga bukyali oluvannyuma lw'okukizuula nti abalwadde abalina "Triple-Positive" Antiphospholipid Syndrome (abalina Lupus Anticoagulant, Anti-Cardiolipin, ne Anti-Beta-2-Glycoprotein-I) abaamira Direct Oral Anticoagulants (DOACs nga rivaroxaban oba apixaban) yafuna emirundi 4 ku mirundi 7 egy’okusannyalala kw’emisuwa n’okulwala omutima okusinga abalwadde abaali bamira Warfarin. Okuziyiza ensonga emu yokka ey’okuzimba omusaayi (Factor Xa oba Factor IIa) ne DOAC kitera obutamala kuyimiriza massive thrombin and complement surge evugirwa antiphospholipid antibodies ezirina emirundi esatu, era okukyusa okuva ku Warfarin okudda ku DOAC kye kivaako ekiwandiikiddwa ku acute Catastrophic APS.

Ensonda n’obulagirizi obutongole¶

• Endagiriro y’enkola y’obujjanjabi eya McMaster University / ASH (Legault K et al., Enkulaakulana y’omusaayi): Endagiriro y’enkola y’obujjanjabi eya McMaster RARE-Bestpractices ey’okuzuula n’okuddukanya obulwadde bwa Catastrophic Antiphospholipid Syndrome (Triple Therapy: Anticoagulation, Glucocorticoids, and Plasma Exchange/IVIG).
• European Alliance of Associations for Rheumatology (EULAR, Tektonidou MG et al., Annals of the Rheumatic Diseases): EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults (Contraindication of DOACs in Triple-Positive APS and CAPS Management).
• International Consensus Statement on Classification Criteria and Treatment Guidelines for Catastrophic Antiphospholipid Syndrome (Asherson RA, Cervera R, et al., Lupus / Journal of Rheumatology): Preliminary Classification Criteria for Definite and Probable CAPS and Analysis of 500+ Patients from the International CAPS Registry.
• British Society for Haematology (BSH, Arachchillage DRJ et al.): Guidelines on the Investigation and Management of Antiphospholipid Syndrome and Catastrophic APS.
• New England Journal of Medicine (NEJM) Review (Garcia D, Erkan D): Diagnosis and Management of the Antiphospholipid Syndrome and Complement Inhibition in CAPS.

Ebiragiro ebikwatagana nabyo¶

• Adrenal crisis and Addison's disease emergency injection
• Heparin-induced thrombocytopenia (HIT) and VITT: 50 percent platelet drop on Day 5 to 10 and Argatroban
• Okukonziba kw’obulwadde bwa Eclampsia, obulwadde bwa HELLP, obulwadde bw’okuzaala nga tebannaba kuzaala, n’okusunsula magnesium
• Obulwadde bwa sepsis ne septic shock
• Ennamba z’amangu okusinziira ku nsi